Diagnostic Performance of $^{18}$F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study

1 Michael J. Morris, MD, 2 Steven P. Rowe, MD, PhD, 3 Michael A. Gorin, MD, 4 Lawrence Saperstein, MD, 5 Frédéric Pouliot, MD, PhD, 6 David Josephson, MD, 7 Jeffrey Y.C. Wong, MD, 8 Austin R. Pantel, MD, 9 Steve Y. Cho, MD, 10 Kenneth L. Gage, MD, PhD, 11 Morien Pier, MD, 12 Andrei Iagaru, MD, 13 Janet H. Pollard, MD, 14 Vivien Wong, PhD, 14 Jessica Jensen, MPH, 14 Tess Lin, PharmD, 14 Nancy Stambler, DrPH, 15 Peter R. Carroll, MD, 16 Barry A. Siegel, MD, and CONDOR Study Group*

Institutional Affiliations

1 Memorial Sloan Kettering Cancer Center, New York, NY
2 The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
3 The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
4 Yale School of Medicine, New Haven, CT
5 CHU de Quebec and Laval University, Quebec City, QC
6 Tower Urology, Cedars Sinai Medical Center, Los Angeles, CA
7 City of Hope, Sierra Madre, CA
8 Hospital of the University of Pennsylvania, Philadelphia, PA
9 University of Wisconsin-Madison, Madison, WI
10 Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
11 Radiology, University of Michigan, Ann Arbor, MI
12 Stanford University, Stanford, CA
13 University of Iowa Hospital, Iowa City, IA
14 Progenics Pharmaceuticals, Inc., New York, NY
15 University of California San Francisco, San Francisco, CA
30 16Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University
31 School of Medicine, St. Louis, Missouri
32 #Contributed equally to this work
33 *See Appendix
34
35 Corresponding Author
36 Michael J. Morris, MD
37 Memorial Sloan Kettering Cancer Center
38 1275 York Ave
39 New York, NY 10065
40 Email: morrism@MSKCC.ORG
41
42 Conflict of interest statement: COI's have been submitted electronically.
43
Translational Relevance

In men with biochemically recurrent prostate cancer (BCR), there is an unmet medical need for accurate disease localization such that treatment planning will be appropriate to the distribution of disease. These clinical decisions are generally made at low PSA values, when standard imaging performs poorly at demonstrating disease. PSMA-targeted PET has been a promising candidate to detect disease otherwise not demonstrated by standard techniques. CONDOR is a prospective, multicenter study designed to demonstrate the diagnostic performance of the PSMA-targeted PET radiotracer $^{18}$F-DCFPyL for regulatory approval. The trial demonstrated that the radiotracer correctly localized disease in approximately 85% of men with BCR, all of whom had uninformative conventional imaging. These findings changed planned management in 64% of men. These data support the use of $^{18}$F-DCFPyL-PET/CT for disease localization in men with BCR, as it is significantly superior to standard imaging.
Abstract

**PURPOSE:** Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). $^{18}$F-DCFPyL is a highly selective, small-molecule PSMA-targeted PET radiotracer. CONDOR was a prospective study designed to determine the performance of $^{18}$F-DCFPyL-PET/CT in patients with BCR and uninformative standard imaging.

**METHODS:** Men with rising PSA $\geq$ 0.2 ng/mL after prostatectomy or $\geq$ 2 ng/mL above nadir after radiation therapy were eligible. The primary endpoint was correct localization rate (CLR) defined as positive predictive value with an additional requirement of anatomic lesion co-localization between $^{18}$F-DCFPyL-PET/CT and a composite standard of truth (SOT). The SOT consisted of, in descending priority: 1) histopathology, 2) subsequent correlative imaging findings, or 3) post-radiation PSA response. The trial was considered a success if the lower bound of the 95% confidence interval for CLR exceeded 20% for 2 of 3 $^{18}$F-DCFPyL-PET/CT readers. Secondary endpoints included change in intended management and safety.

**RESULTS:** 208 men with a median baseline PSA of 0.8 ng/mL (range: 0.2-98.4 ng/mL) underwent $^{18}$F-DCFPyL-PET/CT. The CLR was 84.8%-87.0% (lower bound of 95% CI: 77.8%-80.4%). 63.9% of evaluable patients had a change in intended management after $^{18}$F-DCFPyL-PET/CT. The disease detection rate was 59% to 66% (at least one lesion detected per patient by $^{18}$F-DCFPyL-PET/CT by central readers).

**CONCLUSION:** Performance of $^{18}$F-DCFPyL-PET/CT achieved the study’s primary endpoint, demonstrating disease localization in the setting of negative standard imaging and providing clinically meaningful and actionable information. These data
further support the utility of $^{18}$F-DCFPyL-PET/CT to localize disease in men with recurrent prostate cancer.
A challenging clinical dilemma in the management of prostate cancer is the occurrence of a rising serum prostate specific antigen (PSA) after curative intent surgery or radiation therapy (RT) in the absence of informative conventional imaging. This condition, known as biochemical recurrence (BCR), indicates the presence of persistent or recurrent disease, without defining its location, and occurs in 20-50% of men within 10 years after definitive local therapy. This inability to define recurrent disease localization is an unmet need and reflects the shortcomings of both PSA and current standard-of-care imaging modalities. Conventional imaging (CT; MRI; bone scintigraphy) perform poorly in localizing sites of disease recurrence in patients with BCR, particularly when PSA values are low (<2.0 ng/mL). Novel positron emission tomography (PET) radiotracers, including FDA-approved agents (11C-choline and 18F-fluciclovine), have shown promise, but their predictive performance degrades with PSA levels <2.0 ng/mL. These limitations have stimulated the development of other agents with improved diagnostic performance, including radiotracers targeting the cell surface protein, prostate-specific membrane antigen (PSMA).

18F-DCFPyL is a small molecule that binds to the extracellular domain of PSMA with high affinity and has shown success in studies evaluating the detection of prostate cancer across a range of disease states, including studies where histopathology served as reference standard. Building upon an earlier phase 2/3 multi-center trial (OSPREY) (NCT02981368) that evaluated the performance of 18F-DCFPyL-PET/CT in initial staging of high-risk prostate cancer and in detection of suspected recurrent/metastatic lesions seen on
CONDUCT TRIAL

conventional imaging, CONDOR (NCT03739684) was designed to demonstrate the performance of $^{18}$F-DCFPyL-PET/CT in men with prostate cancer BCR.

METHODS

Trial Design

CONDOR was a phase 3, prospective, multicenter, open-label, single-arm study designed to evaluate the diagnostic performance and safety of $^{18}$F-DCFPyL-PET/CT in patients with suspected recurrent or metastatic prostate cancer with negative or equivocal conventional imaging (including $^{18}$F-fluciclovine or $^{11}$C-choline PET, CT, MRI, and/or whole-body bone scintigraphy) per institutional standard of care. The study was conducted across 13 sites in the United States and one in Canada, and was approved by the Institutional Review Board/Research Ethics Board at each participating institution. The study was conducted in accordance with the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice.

Study Population

Men ≥18 years of age with biochemically recurrent adenocarcinoma of the prostate treated with radical prostatectomy (RP) or RT were eligible for the study. BCR after RP was defined as a rising PSA to ≥0.2 ng/mL. For patients treated with RT, BCR was defined as a PSA value ≥2 ng/mL above the patient’s post-radiation nadir value. All enrolled patients required negative/equivocal findings for prostate cancer on standard-of-care imaging performed 60 days prior to $^{18}$F-DCFPyL injection. Before enrollment, written informed consent was obtained from all patients. Exclusion criteria included administration of any high-energy (>300 KeV) gamma-emitting radioisotope within five physical half-lives prior to $^{18}$F-DCFPyL injection, and
androgen deprivation therapy (ADT) within 3 months of imaging, or investigational
treatment for prostate cancer within 60 days of imaging. Ongoing systemic therapy for
prostate cancer was prohibited. Patients with medical conditions or circumstances
that, in the opinion of the investigator, would compromise the safety or compliance of
the patient to produce reliable data or completing the study were also excluded.

Screening

Demographic information, baseline characteristics (date of birth, race, ethnicity,
height, and weight) and clinically relevant medical history were recorded. The
patient’s prostate cancer medical history, including American Joint Committee on
Cancer stage, Gleason score, pretreatment PSA, and all past/present therapies,
were obtained. Standard-of-care imaging per local practice obtained within 60 days
before $^{18}$F-DCFPyL administration was reviewed. This imaging could include CT or
MRI, bone scintigraphy or PET with $^{18}$F-fluciclovine or $^{11}$C-choline. All baseline
images were submitted to a central imaging core laboratory for assessment. A blood
sample for total PSA obtained at screening or just before administration of $^{18}$F-
DCFPyL from enrolled patients was analyzed by a central core laboratory.

Medical Management Questionnaire

The treating investigator completed a pre-$^{18}$F-DCFPyL Medical Management
Questionnaire (MMQ) to document the initial intended management plan for the
patient based on available clinical information and local baseline imaging results,
including CT, MRI, $^{11}$C-choline and $^{18}$F-fluciclovine PET. Within 60 days after $^{18}$F-
DCFPyL-PET/CT, the treating Investigator completed the post-$^{18}$F-DCFPyL MMQ to
document whether the initial intended management plan had changed.

$^{18}$F-DCFPyL dosing and PET/CT
The protocol-specified dose of $^{18}$F-DCFPyL was 9 mCi (333 MBq) administered intravenously (IV) 1–2 hours before PET/CT (Supplementary Table 1). Patients voided before imaging, and PET and non-contrast CT images were acquired from mid-thigh through skull vertex. All $^{18}$F-DCFPyL-PET/CT scans were submitted to the central imaging core laboratory for assessment. Patients with positive $^{18}$F-DCFPyL-PET/CT scans based on local interpretation were scheduled for subsequent follow-up to verify suspected lesion(s) based on a composite standard of truth (SOT).

(Figure 1)

Tiered Composite SOT

Because of the expected absence of an amenable lesion for histologic verification in most patients, a composite SOT was employed following FDA discussions, based on assessment performed or initiated within 60 days following $^{18}$F-DCFPyL-PET/CT. These reference standards were defined (in order of priority) as (1) evaluable histopathology results from prostatectomy, salvage pelvic lymph node dissection or targeted biopsy; (2) correlative follow-up imaging findings using $^{18}$F-fluciclovine or $^{11}$C-choline PET, or focused MRI or CT; or (3) if neither of the above was available or informative, confirmed PSA response up to 9 months post-radiation initiation (without concomitant ADT) of all PET-positive foci. PSA response was defined as PSA decline by $\geq$50% from baseline that was confirmed on repeat measurement within 4 weeks, based on central laboratory results.

Central Imaging Review

A central imaging core laboratory was employed to independently manage image handling, reader training, reader sessions, and data collection. This review consisted of two discrete imaging evaluations:
1) 

\[^{18}\text{F-DCFPyL-PET/CT}\] assessment was performed by three independent, blinded, board-certified nuclear medicine physicians trained in the interpretation of \[^{18}\text{F-DCFPyL-PET}\]. The readers had no access to any clinical information, including PSA values or other imaging available for a patient. Each reader independently evaluated a patient’s \[^{18}\text{F-DCFPyL-PET/CT}\] study without access to information from either of the other two readers, the Truth Panel, the local Investigator, or study sponsor. Each central reader also measured standardized uptake values (SUVs) on up to 25 PET-positive lesions seen on each scan.

2) Each image obtained as part of the SOT was assessed by two independent, board-certified nuclear medicine and radiology readers (the Truth Panel), who assessed these images in conjunction with the \[^{18}\text{F-DCFPyL-PET/CT}\] images for the presence or absence of prostate cancer. These readers also adjudicated the accuracy of needle placement during image-guided biopsy, if performed. The Truth Panel members were not members of the central \[^{18}\text{F-DCFPyL-PET/CT}\] reader group and were blinded to all data generated by the central \[^{18}\text{F-DCFPyL-PET/CT}\] readers.

**Efficacy Outcomes**

The primary endpoint of the study was the correct localization rate (CLR) of \[^{18}\text{F-DCFPyL-PET/CT}\]. CLR, a novel endpoint recommended by the FDA, is a measure of PPV at the patient level that employed anatomic lesion location matching (co-localization) of a lesion identified by \[^{18}\text{F-DCFPyL-PET/CT}\] central readers and the lesion identified by Truth Panel central readers and/or pathology. CLR was defined as the percentage of patients with a one-to-one correspondence between at
least one lesion identified on $^{18}$F-DCFPyL-PET/CT by the central readers and the composite SOT.

The secondary endpoints were the percentage of patients with a change in intended prostate cancer treatment plans after $^{18}$F-DCFPyL-PET/CT based on the MMQ that was completed pre-and post-$^{18}$F-DCFPyL-PET/CT, as well as safety of $^{18}$F-DCFPyL.

Exploratory endpoints were evaluation of detection rates and PPVs of $^{18}$F-DCFPyL-PET/CT at the region level (i.e., prostate/prostate bed, pelvis, and extra-pelvic regions) and detection rate of $^{18}$F-DCFPyL-PET/CT as a function of baseline PSA ($<0.5$, $0.5–<1.0$, $1.0–<2.0$, $2.0–<5.0$, or $\geq 5.0$ ng/mL).

**Statistical Methods**

A full description of the determination of sample size is provided in the study protocol (Supplementary Appendix). Based on a meta-analysis by Perera et al$^{23}$ of $^{68}$Ga-PSMA PET/CT, approximately 76% of PSMA scans are positive in suspected prostate cancer recurrence. In this study, 60% of the imaged patients were expected to have a positive $^{18}$F-DCFPyL-PET/CT scan and of these 30% were expected to have a confirmatory SOT finding in patients with negative/equivocal baseline imaging. Therefore, $^{18}$F-DCFPyL-PET/CT was expected to detect/localize recurrent disease in approximately 18% of the study population versus $\leq 5\%$ identified by conventional imaging. This required a total of 81 positive $^{18}$F-DCFPyL scans, or 134 evaluable patients. Accounting for a 30% non-evaluable/loss rate, the sample size was 192 patients.

The safety and efficacy populations for analysis consisted of all patients who received $^{18}$F-DCFPyL.

**Primary Endpoint Analysis**
The CLR is computed as $100 \times \frac{TP}{TP + FP}$, where $TP = \text{true positive result}$ and $FP = \text{false positive result}$ for each central imaging reader. A TP result is defined as a patient with both a positive lesion(s) on $^{18}$F-DCFPyL-PET/CT and a positive result on the composite SOT within the same anatomic location as defined within the Statistical Analysis Plan. The classification of the anatomic locations is provided in Supplementary Table 3. A FP result was defined as a patient with positive lesion(s) on $^{18}$F-DCFPyL-PET/CT identified by the central reader with negative findings for prostate cancer according to the composite SOT. The success criterion for the primary endpoint was the lower limit of the 95% CI to exceed 20% for at least 2 of the 3 readers. This criterion was based on data from the performance characteristics of other molecular imaging agents at PSA values <2 ng/mL. The two-sided 95% confidence interval (CI) for CLR for each reader was calculated using the normal approximation for a single binomial variable.

**Secondary Endpoint Analysis**

The percentage of patients with a change in intended prostate cancer treatment plan before and after $^{18}$F-DCFPyL-PET/CT was reported with the corresponding two-sided 95% CI using the normal approximation for the binomial variable.

**Exploratory Endpoint Analysis**

The disease detection rate was defined as the percent of positive $^{18}$F-DCFPyL PET/CT scans identified by the central imaging readers. It was calculated as the number of patients with positive scans divided by the number of patients who have evaluable scan results reported $\times 100\%$. PPV within anatomic regions without lesion-level matching was calculated for patients with positive $^{18}$F-DCFPyL-PET/CT scans as $\frac{TP}{TP + FP} \times 100\%$. Detection rate and PPV by region (i.e., prostate/prostate bed, pelvic, extra-pelvic) and as a function of baseline PSA were
analyzed for each central imaging reviewer and for the local site interpretation separately using a two-sided 95% CI based on a normal approximation to the binomial distribution.

**Inter-and Intra-reader Agreement**

Inter-reader agreement between the central readers at the subject level was assessed using Fleiss’ generalized kappa. Agreement between each central reader and the local reader was calculated using Cohen’s pairwise kappa. For intra-reader agreement, each central reader assessed 42 subjects (20%) twice as part of their reading schedule after a washout period of at least 28 days following the initial review, without knowledge that the cases were read twice. Cohen’s kappa was calculated to assess agreement for each reader. All kappa statistics are reported with their respective 95% confidence intervals.

**Safety Outcomes**

Safety assessments included monitoring for the incidence of treatment-emergent adverse events (AEs) from the time of $^{18}$F-DCFPyL dosing up to 7±3 days post-dose. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.

**RESULTS**

The Standards for Reporting of Diagnostic Accuracy (STARD) flow diagram is depicted in **Figure 1**. 208 patients were enrolled between November 2018 and August 2019. The median age was 68 years (range 43-91); 67.8% were ≥65 years old. The median baseline PSA level was 0.8 ng/mL (range 0.2-98.4); 68.8% of patients had PSA levels <2.0 ng/mL. The median time from the initial prostate cancer diagnosis was 71 months (range 3-356). Prior treatment was RP in 49.5%,
RP and RT in 35.6%, and radiation alone in 14.9%. Baseline characteristics, PET imaging and baseline conventional imaging details are further summarized in Table 1, Supplementary Figure 1 and Supplementary Table 3.

$^{18}$F-DCFPyL-PET/CT detected ≥1 lesion in 59.1% to 65.9% patients as assessed by three independent blinded central readers. The primary endpoint of CLR was met as the lower limit of 95% CI exceeded 20% for all three readers. The CLR ranged from 84.8% to 87.0% among the three readers (the lower bound of the 95% CI ranged from 77.8% to 80.4%) (Table 2).

The performance of $^{18}$F-DCFPyL-PET/CT by CLR and PPV was maintained through all categories of the SOT: histopathology (N=31): 78.6-82.8% and 92.9-93.3% for CLR and PPV, respectively; correlative imaging (N=100): 86.1-88.6% and 87.0-89.5% for CLR and PPV, respectively; and PSA response (N=1): 100% for both CLR and PPV. Further analyses of the correlative imaging results showed CLR remained high across the different modalities used a) $^{18}$F-fluciclovine-PET/CT (N=71): (86.8-90.9%); b) MRI (N=23): (80.0-86.7%); and c) CT (n=6): (80.0-100%) (Supplementary Tables 4-6). The CLRs for each reader also were maintained across prior treatment regimens (Supplementary Table 7) and increased with the within-patient maximum standardized uptake value (SUV$_{\text{max}}$) of lesions identified on $^{18}$F-DCFPyL-PET/CT (Supplementary Table 8).

**CLR by Baseline PSA and Detection Rate**

In patients with baseline PSA levels <0.5 ng/mL, the median CLR was 73.3% while patients with a PSA of ≥5 ng/mL had a median CLR of 96.4 % (Figure 2A and Supplementary Table 9). The detection rate rose with increasing PSA levels ranging from 36.2% (<0.5 ng/mL) to 96.7% (≥5 ng/mL) (Figure 2B and Supplementary Table 10).
Positive Predictive Value by Anatomic Region

PPV of $^{18}$F-DCFPyL-PET/CT was determined in detection of recurrent disease by anatomic regions (prostate/prostate bed, pelvis, and extra-pelvic regions) from the composite SOT in patients with at least one $^{18}$F-DCFPyL-positive lesion. The PPV was consistently high across all anatomic regions. The PPV in the prostatic region ranged between 75.0% and 83.3% among the three independent readers. Similarly, for pelvic lymph nodes, the PPV was between 67.2% and 72.7%, and for the extra-pelvic regions, it ranged from 67.3% to 69.8%. (Figure 3 and Supplementary Tables 11 and 12). The distribution of positive $^{18}$F-DCFPyL-PET/CT findings by anatomic region is shown in Supplementary Table 13.

Inter-and Intra-reader Agreement

Reader agreement results are summarized in Supplementary Table 14. Inter-reader agreement had a concordance of 75% and Fleiss' kappa of 0.65 (95%CI: 0.58, 0.73). Agreement between the central and local readers had concordances of 83.2% to 83.7% and kappas of 0.62 (95%CI: 0.50, 0.73), 0.65 (95%CI: 0.54, 0.75) and 0.64 (95%CI: 0.53,0.74) for the three readers. Intra-reader agreement had kappas of 0.94 (95%CI: 0.82,1.0), 1.0 and 0.81 (95%CI 0.64, 0.98) for the three readers.

Change in Planned Medical Management

The treating physicians completed pre- and post-$^{18}$F-DCFPyL-PET/CT MMQs for 205 patients. Nearly two-thirds (63.9%; n = 131) of these patients had a change in intended disease management plan. Of these 131 patients, 103 (78.6%) were associated with positive $^{18}$F-DCFPyL-PET/CT findings, and 28 (21.4%) were associated with negative findings. Of the 144 patients that had a positive $^{18}$F-
DCFPyL scan, 103 (72.5%) had a recommended change in management. The most frequent changes to treatment management plans after the $^{18}$F-DCFPyL-PET/CT imaging results included salvage local therapy that was either supplemented or replaced by systemic therapy ($n = 58; 28.3%$), observation to initiating therapy ($n = 49; 23.9$%), systemic therapy to salvage local therapy ($n = 43; 21.0%$), and planned treatment to observation ($n = 9; 4.4%$). (Figure 4 and Supplementary Table 15)

Safety Results

Fourteen (6.7%) patients experienced 21 AEs; headache (1.9%), fatigue (1.0%), and hypertension (1.0%) were most frequent. Only one patient (0.5%), with a significant history of allergic reactions, experienced serious, Grade 3 AEs (hypersensitivity, headache, paresthesia), all of which resolved. There were no Grade 4 AEs or deaths.

DISCUSSION

This study was designed to evaluate the performance of $^{18}$F-DCFPyL-PET/CT in prostate cancer patients with BCR and non-informative standard-of-care imaging. CONDOR used a central reader paradigm, and a novel primary efficacy endpoint with a composite SOT. The study demonstrated a high CLR that suggests $^{18}$F-DCFPyL-PET/CT is a superior and reliable tool for the detection and localization of sites of disease in men with BCR relative to conventional imaging.

The CONDOR population generally represents BCR patients with low PSA values (median PSA 0.8 ng/mL), when crucial clinical decisions are made as to whether the patient warrants salvage local or metastasis-directed therapy with curative intent, or systemic therapy without curative intent, or some combination of local and systemic treatments. An accurate understanding of the location and burden of disease is key
to well-informed treatment planning. In our study population, the PSA was <2.0 ng/mL in 68.8% of patients, <1.0 ng/mL in 52.5% and <0.5 ng/mL in 34.2%. As such, the study provides prospective evidence of diagnostic accuracy to reliably detect prostate cancer recurrence or metastases in patients in whom currently available conventional imaging and approved molecular imaging modalities are suboptimal. Notably, a total of 59.6% to 65.9% of patients had at least one occult lesion detected among the three readers and the CLR was consistently high across all SOT determinations, anatomic regions, and in patients with PSA 0.2 to <2.0 ng/mL (>73%). This performance of $^{18}$F-DCFPyL-PET/CT is substantially better than the reported detection rates and PPVs of $^{18}$F-fluciclovine- and $^{11}$C-choline-PET in patients with similar PSA ranges, although each tracer may behave differently depending on risk factors beyond absolute PSA value, such as Gleason grade, growth rate, histologic subtype, and other measures.$^{11,12,15}$

Another PSMA-targeted PET radiopharmaceutical, $^{68}$Ga-PSMA-11, is widely used in clinical practice outside of the United States and recently received FDA approval.$^{26}$ In a prospective study by Fendler et al., this imaging agent had similar results, with PPV of 0.84 (95% CI, 0.75-0.90) by histopathologic comparator (primary endpoint, n = 87) and 0.92 (95% CI, 0.88-0.95) by a composite reference standard, in men with BCR; of note, unlike CONDOR, in Fendler’s study, patients were eligible irrespective of prior conventional imaging findings.$^{27}$ Eiber et al. was one of the first to report positive findings with $^{68}$Ga-PSMA-11 in post-RP BCR patients with low PSA values (<0.5 ng/mL).$^{28}$ However, retrospective studies with $^{68}$Ga-PSMA-11, while including prespecified endpoints and statistical designs, did not require negative standard imaging.$^{29,30}$
This study furnishes direct evidence that clinicians intend to utilize the additional information provided by the $^{18}$F-DCFPyL scan to revise their treatment plans and goals of care relative to their original plans based on clinical presentation and non-informative standard imaging. The ability of $^{18}$F-DCFPyL-PET/CT to localize and detect the extent of recurrent disease offers physicians the opportunity to adjust and tailor their treatment planning and potentially improve treatment outcomes in men with recurrent prostate cancer. Although change in patient management after PET occurred frequently, this study was not designed to determine whether such changes were implemented or ultimately benefited patients. Further, this study, which was designed to establish the relationship between a positive imaging finding and a positive composite standard of truth, does not establish that a given PSMA-avid lesion represents the only lesion that is producing PSA, or that a specifically identified lesion represents the clone of the disease likely to be lethal for the patient. However, a recent multicenter prospective study of PET/CT using $^{68}$Ga-PSMA-11 did show that negative or prostate-bed-only positive findings were highly predictive of response to salvage RT after RP. These results show that PSMA-PET can help to select patients most likely to benefit from a particular therapy. However, future studies will be necessary to demonstrate whether $^{18}$F-DCFPyL-PET/CT-directed changes in management lead to improved outcomes for prostate cancer patients with BCR.

While prospective single-center trials with $^{18}$F-DCFPyL-PET imaging in BCR have been reported recently, only Mena et al. reported PPV verified by a composite SOT. CONDOR represents the first multicenter prospective trial of $^{18}$F-DCFPyL-PET for the BCR population. By design, the study focused on CLR, which fundamentally is a patient-level PPV with the added criterion of anatomic co-
localization. Consequently, a limitation of this study is that the “truth” in men with negative $^{18}$F-DCFPyL-PET/CT per local radiology assessment is unknown, because verification of $^{18}$F-DCFPyL-PET/CT results was not required in such patients. Trying to find occult disease not detected by PET would have required following these patients without treatment to see if the disease became evident over time; this was not a practical or ethical option. Thus, we cannot determine whether these false-negative cases reflect PSMA-negative disease (which occurs in 5-10% of prostate cancers),$^{34}$ inexperience of local readers, or small-volume disease (similar to the poor detection of small nodal deposits in OSPREY Cohort A),$^{20}$ or obscuration of lesions in or adjacent to organs with high uptake of $^{18}$F-DCFPyL (e.g., liver) or structures-containing excreted tracer (ureters, bladder, urethra). Accordingly, the negative predictive value of $^{18}$F-DCFPyL-PET/CT in this patient population with non-informative standard imaging could not be assessed.

PSMA-targeted PET radiopharmaceuticals labeled with $^{18}$F can offer an alternative to $^{68}$Ga agents. There are few direct comparisons of the two tracers,$^{35,36}$ but these suggest that the performance of $^{18}$F-DCFPyL is similar to that of the $^{68}$Ga agents. In summary, this study met its primary endpoint of high CLR and demonstrated that the additional information provided by $^{18}$F-DCFPyL-PET/CT was associated with frequent changes in disease management plans. These data support $^{18}$F-DCFPyL-PET/CT as a safe and robust imaging tool to reliably detect recurrent prostate cancer, even at low PSA levels, thus providing new actionable information by the localization of otherwise occult disease.
Acknowledgements

We thank the participants who volunteered to take part in this trial, as well as blinded readers, truth panel members, and all members of the trial teams at each participating institution. This study was funded by Progenics Pharmaceuticals, Inc.
References


25. AXUMIN (fluciclovine F 18) injection, for intravenous use [prescribing information].

condor trial


### Table 1. Baseline characteristics and $^{18}$F-DCFPyL dosing/uptake time

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n = 208</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years): median (range)</td>
<td>68 (43, 91)</td>
</tr>
<tr>
<td>Age ≥65 years, n (%)</td>
<td>141 (67.8)</td>
</tr>
<tr>
<td>Months from prostate cancer diagnosis: median (range)</td>
<td>71 (3, 356)</td>
</tr>
<tr>
<td>Prior prostate cancer therapies</td>
<td></td>
</tr>
<tr>
<td>RP only, n (%)</td>
<td>103 (49.5)</td>
</tr>
<tr>
<td>RT only, n (%)</td>
<td>31 (14.9)</td>
</tr>
<tr>
<td>RP and RT, n (%)</td>
<td>74 (35.6)</td>
</tr>
<tr>
<td>At least 1 prior systemic therapy, n (%)</td>
<td>58 (27.9)</td>
</tr>
<tr>
<td>Total Gleason Score, n (%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 8</td>
<td>153 (73.6)</td>
</tr>
<tr>
<td>&lt; 6</td>
<td>3 (1.4)</td>
</tr>
<tr>
<td>$3 + 3 = 6$</td>
<td>12 (5.8)</td>
</tr>
<tr>
<td>$3 + 4 = 7$</td>
<td>78 (37.5)</td>
</tr>
<tr>
<td>$4 + 3 = 7$</td>
<td>60 (28.8)</td>
</tr>
<tr>
<td>≥ 8</td>
<td>55 (26.4)</td>
</tr>
<tr>
<td>$3 + 5 = 8$</td>
<td>0</td>
</tr>
<tr>
<td>$4 + 4 = 8$</td>
<td>21 (10.1)</td>
</tr>
<tr>
<td>$5 + 3 = 8$</td>
<td>0</td>
</tr>
<tr>
<td>$4 + 5 = 9$</td>
<td>31 (14.9)</td>
</tr>
<tr>
<td>$5 + 4 = 9$</td>
<td>3 (1.4)</td>
</tr>
<tr>
<td>$5 + 5 = 10$</td>
<td>0</td>
</tr>
<tr>
<td>PSA (ng/mL) (n=202): Median (range)</td>
<td>0.8 (0.17, 98.45)</td>
</tr>
<tr>
<td>PSA sample collection study day prior to administration of $^{18}$F-DCFPyL (Study Day) (n=202): Median (range)</td>
<td>1 (-29, 1)</td>
</tr>
<tr>
<td>PSA Group (n=202), n (%)</td>
<td></td>
</tr>
<tr>
<td>&lt;2.0 ng/mL</td>
<td>139 (68.8)</td>
</tr>
<tr>
<td>&lt;0.5 ng/mL</td>
<td>69 (34.2)</td>
</tr>
<tr>
<td>0.5 to &lt;1.0 ng/mL</td>
<td>37 (18.3)</td>
</tr>
<tr>
<td>1.0 to &lt;2.0 ng/mL</td>
<td>33 (16.3)</td>
</tr>
<tr>
<td>≥2.0 ng/mL</td>
<td>63 (31.2)</td>
</tr>
<tr>
<td>2.0 to &lt;5.0 ng/mL</td>
<td>33 (16.3)</td>
</tr>
<tr>
<td>≥5.0 ng/mL</td>
<td>30 (14.9)</td>
</tr>
<tr>
<td>$^{18}$F-DCFPyL dosing and uptake time</td>
<td></td>
</tr>
<tr>
<td>Administered activity (mCi/MBq): median (range)</td>
<td>9.42 (7.49-11.07)/349 (277-410)</td>
</tr>
<tr>
<td>Time from injection to imaging (minutes): median (range)</td>
<td>79 (59-115)</td>
</tr>
</tbody>
</table>

**Abbreviations:** PSA: Prostate-specific antigen; RP: Radical prostatectomy; RT: Radiation therapy
Table 2. Disease detection and CLR rate across three independent readers

<table>
<thead>
<tr>
<th></th>
<th>All Patients (n=208)</th>
<th>Reader 1 95% CI (%)</th>
<th>Reader 2 95% CI (%)</th>
<th>Reader 3 95% CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative PyL Scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71 (34.1%) (27.7, 40.6)</td>
<td>84 (40.4%) (33.7, 47.1)</td>
<td>85 (40.9%) (34.2, 47.5)</td>
<td></td>
</tr>
<tr>
<td>Positive PyL Scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>137 (65.9%) (59.4, 72.3)</td>
<td>124 (59.6%) (52.9, 66.3)</td>
<td>123 (59.1%) (52.5, 65.8)</td>
<td></td>
</tr>
<tr>
<td>Unevaluable*</td>
<td>33</td>
<td>24</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>CLR (TP/TP+FP)</td>
<td>89/104 (85.6%) (78.8, 92.3)</td>
<td>87/100 (87.0%) (80.4, 93.6)</td>
<td>84/99 (84.8%) (77.8, 91.9)</td>
<td></td>
</tr>
</tbody>
</table>

*Some patients were unevaluable for the primary endpoint, either because no SOT was submitted (between 17-25 patients, depending on the central reader), or because the ¹⁸F-DCFPyL-PET/CT scan was deemed a false negative based on lesion level co-localization (7-8 patients), which was not a component of the primary endpoint calculation (due in part to the lack of specificity of comparative conventional imaging modalities).
Figure 1. STARD flow diagram with Composite Standard of Truth (SOT) Validation

Includes patients who withdrew from the study or did not have follow-up assessment due to negative $^{18}$F-DCFPyL-PET/CT per local read;

EBRT = external beam radiation therapy
Figure 2. CLR (A) and detection rate (B) by baseline PSA levels

*Median (95% CI) for each group of three readers provided

Abbreviations: CLR: Correct localization rate; PSA: Prostate-specific antigen
Figure 3. PPV by anatomic region (A) and extra-pelvic region (B)

*Median (95% CI) for each group of three readers provided; PPV: Positive predictive value
Figure 4. Change in Planned Medical Management
217 patients consented

208 underwent \(^{18}\text{F-DCFPyL-PET/CT}\)

132 patients with lesion follow-up by SOT

- 31 with pathology

- 100 with correlative imaging

- 1 with PSA response to EBRT

76 patients with no SOT submitted*

9 screen failures
Figure 2

A) 

<table>
<thead>
<tr>
<th>Range</th>
<th>Reader 1</th>
<th>Reader 2</th>
<th>Reader 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5 ng/mL</td>
<td>73.3 (51.0, 95.7)</td>
<td>75.0 (53.8, 96.2)</td>
<td>83.3 (66.1, 100)</td>
</tr>
<tr>
<td>0.5-&lt;1.0 ng/mL</td>
<td>79.3 (59.2, 99.3)</td>
<td>80.0 (61.9, 98.2)</td>
<td>88.3 (71.1, 100)</td>
</tr>
<tr>
<td>1.0-&lt;2.0 ng/mL</td>
<td>94.5 (75.8, 100)</td>
<td>95.0 (77.2, 100)</td>
<td>96.3 (80.1, 100)</td>
</tr>
<tr>
<td>2.0-&lt;5.0 ng/mL</td>
<td>94.0 (76.1, 100)</td>
<td>94.0 (76.1, 100)</td>
<td>95.0 (77.2, 100)</td>
</tr>
<tr>
<td>≥5 ng/mL</td>
<td>94.5 (75.8, 100)</td>
<td>95.0 (77.2, 100)</td>
<td>96.3 (80.1, 100)</td>
</tr>
</tbody>
</table>

B) 

<table>
<thead>
<tr>
<th>Range</th>
<th>Reader 1</th>
<th>Reader 2</th>
<th>Reader 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5 ng/mL</td>
<td>36.2 (24.9, 47.6)</td>
<td>51.4 (35.2, 67.5)</td>
<td>66.7 (50.6, 82.8)</td>
</tr>
<tr>
<td>0.5-&lt;1.0 ng/mL</td>
<td>59.6 (41.5, 77.7)</td>
<td>68.6 (52.5, 84.7)</td>
<td>84.8 (72.6, 97.1)</td>
</tr>
<tr>
<td>1.0-&lt;2.0 ng/mL</td>
<td>96.7 (79.4, 100)</td>
<td>97.0 (80.2, 100)</td>
<td>98.3 (81.5, 100)</td>
</tr>
<tr>
<td>2.0-&lt;5.0 ng/mL</td>
<td>97.0 (80.2, 100)</td>
<td>98.3 (81.5, 100)</td>
<td>99.3 (82.7, 100)</td>
</tr>
<tr>
<td>≥5 ng/mL</td>
<td>97.0 (80.2, 100)</td>
<td>98.3 (81.5, 100)</td>
<td>99.3 (82.7, 100)</td>
</tr>
</tbody>
</table>
Figure 3

A) Prostatic (M0) n=39
- Reader 1: 79.5 (66.8, 92.2)
- Reader 2: 70.9 (58.9, 82.9)
- Reader 3: 67.4 (53.8, 80.9)

Pelvic Lymph Nodes (N1) n=55
- Reader 1: 79.5 (66.8, 92.2)
- Reader 2: 70.9 (58.9, 82.9)
- Reader 3: 67.4 (53.8, 80.9)

Extra-Pelvic (M1) n=46
- Reader 1: 79.5 (66.8, 92.2)
- Reader 2: 70.9 (58.9, 82.9)
- Reader 3: 67.4 (53.8, 80.9)

B) Lymph nodes (M1a) n=26
- Reader 1: 61.5 (42.8, 80.2)
- Reader 2: 62.5 (43.1, 81.9)
- Reader 3: 28.6 (7.6, 64.8)

Bone (M1b) n=24
- Reader 1: 61.5 (42.8, 80.2)
- Reader 2: 62.5 (43.1, 81.9)
- Reader 3: 28.6 (7.6, 64.8)

Visceral/soft tissue (M1c) n=7
- Reader 1: 61.5 (42.8, 80.2)
- Reader 2: 62.5 (43.1, 81.9)
- Reader 3: 28.6 (7.6, 64.8)
208 BCR prostate cancer patients (median PSA level was 0.8 ng/mL)

131: Change in management (131/205 (63.9%) of patients)
- 103 (78.6%)
- 28 (21.4%)

74: No change to planned treatment
- 39 (52.7%)
- 35 (47.3%)

58: Salvage local therapy to systemic therapy (n = 58)
- 40 (78.6%)
- 18 (21.4%)

43: Noncurative systemic therapy to salvage local therapy (n = 43)
- 25 (58.1%)
- 18 (41.9%)

49: Observation to initiating therapy (n = 49)
- 48 (98.0%)
- 1 (2.0%)

9: Planned treatment to observation (n = 9)
- 3 (33.3%)
- 6 (66.7%)

Patients with a positive 18F-DCFPyL scan

Patients with a negative 18F-DCFPyL scan

Figure 4
Clinical Cancer Research

Diagnostic Performance of $^{18}$F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study

Michael J. Morris, Steven P. Rowe, Michael A. Gorin, et al.

Clin Cancer Res  Published OnlineFirst February 23, 2021.